Posted by Michael Wonder on 08 Aug 2019
Molecular Partners’ strategic partner Allergan announced today that EMA has validated the marketing authorisation application for abicipar
6 August 2019 - Molecular Partners today announced that the EMA has validated the marketing authorisation application of its strategic partner Allergan for abicipar, a novel DARPin therapy for the treatment of nAMD.
If approved, abicipar is expected to be the first anti-VEGF therapy to sustain vision gains on a true fixed 12-week dosing interval. The validation of the MAA confirms that the submission by the EMA is sufficiently complete to begin the formal review process.
